Updates to ADA’s Handbook; Osteoporosis Patch Flops; Healthy Diet Prolongs Life
The American Diabetes Association (ADA) announced updates to its Standards of Medical Care in…
Browsing Tag
abaloparatide
Radius Announces Update on TYMLOS® (abaloparatide) Label
FDA approved the removal of the boxed warning from the TYMLOS label, effective December 22, 2021The boxed warning had referred to the potential risk of osteosarcomaAction follows review of…
Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal…
The wearABLe study did not demonstrate non-inferiority of abalo-TDS to TYMLOS®Lumbar spine BMD at 12 months vs. baseline for abalo-TDS was +7.1% vs. TYMLOS +10.9%Both abalo-TDS and TYMLOS…
Radius Announces Positive Phase 3 Topline Results for TYMLOS® (abaloparatide)…
ATOM study met the primary endpoint of change in lumbar spine bone mineral density at 12 months (p-value < 0.0001)Study also met secondary endpoints relating to bone mineral density…